National Institute for Health and Care Excellence

(asked on 25th January 2022) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 January 2022 to Question 96910 on National Institute for Health and Care Excellence, how many oncology technical appraisals have been rescheduled in the last six months directly as a result of NICE operational challenges; and what the average time taken has been to reschedule those appraisals.


Answered by
Edward Argar Portrait
Edward Argar
Minister of State (Ministry of Justice)
This question was answered on 31st January 2022

The National Institute for Health and Care Excellence (NICE) has rescheduled one appraisal of an oncology technology in the last six months for operational reasons. NICE’s appraisal of pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer has been delayed by approximately three months due to the volume of topics in its work programme. NICE’s final guidance is expected to be published in November 2022.

Reticulating Splines